Shares of Teva Pharmaceutical Industries Ltd (NYSE:TEVA) have received a consensus rating of “Hold” from the twenty-three brokerages that are currently covering the stock, MarketBeat reports. Three equities research analysts have rated the stock with a sell recommendation, fifteen have assigned a hold recommendation, four have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $21.04.
Several research firms have recently weighed in on TEVA. Zacks Investment Research upgraded Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating and set a $24.00 price objective on the stock in a report on Monday, December 3rd. Bank of America reiterated a “buy” rating and set a $24.00 price objective on shares of Teva Pharmaceutical Industries in a report on Tuesday, February 5th. HSBC set a $12.00 price objective on Teva Pharmaceutical Industries and gave the company a “sell” rating in a report on Tuesday, February 5th. Credit Suisse Group reiterated a “hold” rating and set a $26.00 price objective on shares of Teva Pharmaceutical Industries in a report on Tuesday, February 5th. Finally, Piper Jaffray Companies upgraded Teva Pharmaceutical Industries from an “underweight” rating to a “neutral” rating and lifted their price objective for the company from $15.00 to $16.00 in a report on Wednesday, January 23rd.
NYSE:TEVA opened at $16.47 on Friday. Teva Pharmaceutical Industries has a fifty-two week low of $14.59 and a fifty-two week high of $25.96. The company has a current ratio of 0.96, a quick ratio of 0.63 and a debt-to-equity ratio of 1.69. The stock has a market cap of $16.75 billion, a PE ratio of 5.88, a price-to-earnings-growth ratio of 2.96 and a beta of 1.34.
In other Teva Pharmaceutical Industries news, VP Hafrun Fridriksdottir sold 1,643 shares of the business’s stock in a transaction that occurred on Wednesday, January 2nd. The stock was sold at an average price of $15.70, for a total transaction of $25,795.10. Following the transaction, the vice president now owns 13,469 shares of the company’s stock, valued at approximately $211,463.30. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Deborah A. Griffin sold 4,107 shares of the business’s stock in a transaction that occurred on Monday, March 4th. The stock was sold at an average price of $16.88, for a total value of $69,326.16. Following the transaction, the insider now directly owns 2,941 shares in the company, valued at approximately $49,644.08. The disclosure for this sale can be found here. Insiders sold a total of 16,173 shares of company stock worth $273,316 in the last 90 days. Company insiders own 0.43% of the company’s stock.
Large investors have recently bought and sold shares of the business. Bruderman Asset Management LLC increased its holdings in shares of Teva Pharmaceutical Industries by 2,175.0% during the 4th quarter. Bruderman Asset Management LLC now owns 2,366 shares of the company’s stock worth $36,000 after acquiring an additional 2,262 shares during the last quarter. Rational Advisors LLC acquired a new position in shares of Teva Pharmaceutical Industries during the 4th quarter worth approximately $49,000. Capital Investment Advisory Services LLC acquired a new position in shares of Teva Pharmaceutical Industries during the 4th quarter worth approximately $56,000. Quadrant Capital Group LLC increased its holdings in shares of Teva Pharmaceutical Industries by 420.3% during the 4th quarter. Quadrant Capital Group LLC now owns 5,541 shares of the company’s stock worth $80,000 after acquiring an additional 4,476 shares during the last quarter. Finally, Whittier Trust Co. increased its holdings in shares of Teva Pharmaceutical Industries by 35.4% during the 4th quarter. Whittier Trust Co. now owns 5,481 shares of the company’s stock worth $84,000 after acquiring an additional 1,434 shares during the last quarter. 66.42% of the stock is currently owned by hedge funds and other institutional investors.
About Teva Pharmaceutical Industries
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.
Featured Story: What is Liquidity?
Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.